NCT04448964View on ClinicalTrials.gov

A Study of JNJ-70033093 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

November 14, 2020

Study Completion Date

November 14, 2020

Conditions

Healthy

Interventions

DRUG

JNJ-70033093

JNJ-70033093 will be administered orally as per assigned treatment sequence.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04448964 - A Study of JNJ-70033093 in Healthy Participants | Biotech Hunter | Biotech Hunter